Does oral anticoagulation with edoxaban or apixaban reduce the risk of stroke in patients with device-detected atrial fibrillation?
Patients with device-detected atrial fibrillation (meta-analysis of 2 large randomized trials: NOAH-AFNET 6 and ARTESiA)
Oral anticoagulation with direct oral anticoagulants (edoxaban or apixaban)
Strokehard clinical
In patients with device-detected atrial fibrillation, oral anticoagulation with edoxaban or apixaban effectively reduces stroke risk at the cost of increased major bleeding.
The results of the NOAH-AFNET 6 and ARTESiA trials are consistent with each other. Meta-analysis of these 2 large randomized trials provides high-quality evidence that oral anticoagulation with edoxaban or apixaban reduces the risk of stroke in patients with device-detected atrial fibrillation and increases the risk of major bleeding.
Building similarity graph...
Analyzing shared references across papers
Loading...
McIntyre et al. (Sun,) studied this question.
www.synapsesocial.com/papers/69d570ea75589c71d767e01d — DOI: https://doi.org/10.1161/circulationaha.123.067512
William F. McIntyre
Alexander P. Benz
Nina Becher
Circulation
Imperial College London
Duke University
McMaster University
Building similarity graph...
Analyzing shared references across papers
Loading...